At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
AMPH ER Tab 5, 10, 15 and 20 mg +1 moredrug
Likely dose
AMPH ER Tab 5, 10, 15 and 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
In Brief
A Phase 3 clinical trial evaluating AMPH ER Tab 5, 10, 15 and 20 mg and AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg for ADHD. Completed, enrolled 130 participants across 3 sites.
Detailed Summary
To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
CollaboratorsPremier Research
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedFeb 2019
Primary CompletionOct 2019
TodayJul 2026
First PostedFeb 8, 2019
Enrollment StartFeb 6, 2019
Primary CompletionOct 19, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.4 years ago
Interventions
AMPH ER Tab 5, 10, 15 and 20 mgdrug
Amphetamine
AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mgdrug
Placebo